When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...
BASEL, Switzerland--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...
The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...
FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA ® ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of ...
HANGZHOU, China and SAN FRANCISCO, April 13, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies ...
The US Food and Drug Administration (FDA) has granted approval to a tablet formulation of BeOne Medicines’ targeted cancer drug Brukinsa (zanubrutinib). The company formerly known as BeiGene announced ...
New formulation provides patients with a simplified dosing experience-reducing pill burden and enhancing ease of administration-while preserving flexible dosing options BeOne Medicines Ltd. (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback